E 2307
Alternative Names: E-2307Latest Information Update: 09 Oct 2015
At a glance
- Originator Eisai Co Ltd
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 30 Oct 2014 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly, In volunteers) in Japan (PO)